- Home
- QUIK vs SKYE Comparison
QUIK vs SKYE Comparison
Compare QUIK & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- SKYE
- Stock Information
- Founded
- QUIK 1988
- SKYE 2012
- Country
- QUIK United States
- SKYE United States
- Employees
- QUIK N/A
- SKYE N/A
- Industry
- QUIK Semiconductors
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- QUIK Technology
- SKYE Health Care
- Exchange
- QUIK Nasdaq
- SKYE Nasdaq
- Market Cap
- QUIK 100.1M
- SKYE 101.3M
- IPO Year
- QUIK 1997
- SKYE N/A
- Fundamental
- Price
- QUIK $5.65
- SKYE $3.29
- Analyst Decision
- QUIK Strong Buy
- SKYE Buy
- Analyst Count
- QUIK 3
- SKYE 7
- Target Price
- QUIK $10.87
- SKYE $15.50
- AVG Volume (30 Days)
- QUIK 226.2K
- SKYE 304.9K
- Earning Date
- QUIK 08-12-2025
- SKYE 08-07-2025
- Dividend Yield
- QUIK N/A
- SKYE N/A
- EPS Growth
- QUIK N/A
- SKYE N/A
- EPS
- QUIK N/A
- SKYE N/A
- Revenue
- QUIK $18,359,000.00
- SKYE N/A
- Revenue This Year
- QUIK $11.58
- SKYE N/A
- Revenue Next Year
- QUIK $40.23
- SKYE N/A
- P/E Ratio
- QUIK N/A
- SKYE N/A
- Revenue Growth
- QUIK N/A
- SKYE N/A
- 52 Week Low
- QUIK $4.26
- SKYE $1.14
- 52 Week High
- QUIK $13.36
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- QUIK 44.07
- SKYE 44.67
- Support Level
- QUIK $5.31
- SKYE $3.23
- Resistance Level
- QUIK $5.92
- SKYE $3.75
- Average True Range (ATR)
- QUIK 0.45
- SKYE 0.30
- MACD
- QUIK -0.05
- SKYE -0.02
- Stochastic Oscillator
- QUIK 30.77
- SKYE 29.76
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.